摘要
目的分析埃克替尼联合体部立体定向放射(stereotactic body radiation therapy,SBRT)治疗表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变的转移性非鳞状非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效。方法选取2020年6月至2021年6月山西医科大学山西白求恩医院收治的EGFR基因突变转移性非鳞状NSCL患者110例,采用随机数字表法分为对照组和观察组,每组55例。对照组采用埃克替尼联合常规治疗,观察组采用埃克替尼联合SBRT治疗。比较两组的客观缓解率、预后生存情况、不良反应发生情况及治疗前后的血清肿瘤标志物水平变化。结果观察组的客观缓解率高于对照组,无进展生存期长于对照组,差异均有显著性(P<0.05)。两组的总生存时间及不良反应发生率比较差异无显著性(P>0.05)。治疗后两组患者的血清癌胚抗原、鳞状细胞癌抗原、细胞角蛋白19片段抗原水平均明显低于治疗前,且观察组明显低于对照组,差异均有显著性(P<0.05)。结论EGFR基因突变的转移性非鳞状NSCLC患者应用埃克替尼联合SBRT治疗可提高疗效,延长无进展生存期,安全性较好。
Objective To analyze the clinical effect of ectinib combined with stereotactic body radiation therapy(SBRT)on metastatic nonsmall cell lung cancer(NSCLC)with epidermal growth factor receptor(EGFR)mutation.Method A total of 110 patients with EGFRmutant metastatic non-squamous NSCL admitted to the Shanxi Bethune Hospital were selected and randomly divided into groups.The control group(55 cases)received icotinib combined with conventional radiotherapy.The observation group(55 cases)received Icotinib combined with SBRT.The pathological remission,prognosis and survival,the occurrence of adverse reactions and the changes of serum tumor markers before and after treatment were compared between the two groups.Result The objective remission rate of the observation group was higher than that of the control group(P<0.05).The progression-free survival(PFS)of the observation group was longer than that of the control group(P<0.05).There was no significant difference in overall survival time(OS)between the two groups(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the serum carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC-Ag)and cytokeratin 19-fragment anti-21-1(CYFRA21-1)levels in both groups decreased,and the observation group was lower than the control group.group(P<0.05).Conclusion Icotinib combined with SBRT can improve the efficacy and prolong progression-free survival in patients with metastatic non-squamous NSCLC with EGFR mutation,and the safety is acceptable.
作者
郭艺彤
杨卫华
杨泽华
Guo Yitong;Yang Weihua;Yang Zehua(Department of Respiratory and Critical Care Medicine,Shanxi Bethune Hospital,Shanxi Medical University,Shanxi Taiyuan 030000,China;Department of Respiratory Medicine,Shanxi Cancer Hospital,Shanxi Taiyuan 030000,China;Laboratory of the first hospital of Shanxi Medical University,Shanxi Taiyuan 030000,China)
出处
《中国医刊》
CAS
2023年第4期386-390,共5页
Chinese Journal of Medicine
基金
山西省基础研究计划(2012011041-2)。
